No Data
Veritas In Silico---Revision of the Financial Estimates for the full year ending December 2024.
On the 13th, Veritas In Silico <130A> announced a revision of its financial estimates for the fiscal year ending December 2024, based on recent performance trends. The revised financial estimates for the fiscal year 2024 (January-December 2024) show business revenue decreased by 72.0% compared to the previous estimate to 0.189 billion yen, an operating profit of a negative 0.214 billion yen, ordinary profit of a negative 0.235 billion yen, net income of a negative 0.238 billion yen, and net income per share to
Dream Arts, along with Classicom and others.
Below is the downward revision of VIS, with this period's operating profit and loss forecast at -0.214 billion yen, down from -0.144 billion yen. The approximately 0.268 billion yen gain from the sale of Nisso's subsidiary stocks is expected to be recorded as extraordinary profit. A revision of the performance forecast for Astroscale shows this period's project revenue forecast at 12 billion yen, down from 18 billion yen. A public tender offer by Shannon Innovation for Stock 3970 will be made at a price of 650 yen per share, and the listing is expected to be maintained after the public tender offer, with the remaining 25th new share rights.
Askul, 2Q operating profit decreased by 16.8%, 6.028 billion yen.
The results for the second quarter of the fiscal year ending May 2025, announced by Askul (2678), showed revenue of 237.9 billion 32 million yen, an increase of 2.9% compared to the same period last year, and operating profit of 6 billion 28 million yen, a decrease of 16.8%. Regarding the E-Commerce business, all sectors grew steadily; however, alongside a decline in gross profit margin due to foreign exchange impacts, an increase in fixed costs related to the rental costs of "ASKUL Kanto DC" resulted in increased revenue but decreased profits. [Positive Evaluation] (3399) Yamaoka-ya Sanbai | (6630) Ya
Veritas In Silico Revises FY2024 Forecast Amid Contract Delays
Veritas In Silico's Strategic Shift to Specialty Pharma
Veritas In Silico: Notice regarding revisions to the full-year earnings forecast for the fiscal year ending 2024/12
No Data